<DOC>
	<DOCNO>NCT00312780</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine activity , safety tolerability XL784 give daily patient albuminuria due diabetic nephropathy . XL784 small molecule reno-protective metalloproteinase inhibitor , inhibit ADAMs ( include ADAM10 , target significant interest important role blood vessel formation cell proliferation , ADAM17/TACE , activation associate renal deterioration ) MMPs ( include MMP-2 MMP-9 ) . XL784 specifically optimize MMP-1 sparing , may clinically significant inhibition MMP-1 hypothesize associate musculoskeletal toxicity .</brief_summary>
	<brief_title>Study XL784 Patients With Albuminuria Due Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Type 1 Type 2 diabetes mellitus albuminuria , observe within 3 month screen Prior randomization , subject glomerular filtration rate ( GFR ) &gt; /= 40 mL/min Prior randomization , subject albuminuria define ACR &gt; /= 500 mg/g Stable seat blood pressure screen visit prior randomization Subject stable dose schedule angiotension convert enzyme ( ACE ) inhibitor and/or angiotension receptor blocker ( ARB ) least 3 month first dose study drug If antidiabetic medication , subject stable dose schedule least 3 month prior first dose study drug Sexually active subject must use accepted method contraception course study 3 month Signed informed consent Subject participate investigational study receive investigational drug within 30 day first dose XL784 Hemoglobin A1c ( HbA1c ) value &gt; 10 % screening Subject either organ transplantation currently immunosuppressive therapy Nonsteroidal antiinflammatory drug ( NSAIDs ) within 5 day urine screening assessment Current diagnosis one follow condition : 1 ) infection require parenteral antibiotic , 2 ) urinary tract infection , 3 ) hepatic dysfunction disease , 4 ) symptomatic congestive heart failure , 5 ) unstable angina pectoris , 5 ) serious cardiac arrhythmia Clinically evident diabetic gastroparesis motility disturbance Proteinuria due diabetic nephropathy Diltiazem verapamil Ongoing condition treatment NSAIDs anticipate ( aspirin &lt; /= 325 mg/day allow ) Recent history drug alcohol abuse Pregnant breastfeed female subject Known HIV and/or receive antiretroviral therapy Known allergy hypersensitivity component XL784 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>albuminuria</keyword>
	<keyword>diabetic nephropathy</keyword>
	<keyword>diabetes</keyword>
</DOC>